The drug is now the only available treatment for the condition that specifically targets inflammation.
A randomized phase 3 trial of the drug revealed that after 12 weeks of treatment, 65% of patients achieved clinical response and 24% achieved clinical remission. Other side effects from the condition including rectal bleeding and frequency of excrement improved after week three for many patients.
“Omvoh addresses key symptoms that matter most to patients and represents our patient-centric approach to treatment innovation,” said Patrik Jonsson, Lilly’s executive vice president and chief customer officer. “Omvoh’s approval is a significant moment for Lilly’s growing Immunology portfolio.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
